Pelubiprofen

ApprovedSmall molecule

Daewon Pharmaceutical Co., Ltd.

Pelubiprofen is one of 151 small molecule programs targeting Respiratory tract infection. It is currently in Approved.

Indications

Total Trials

Active Trials

150

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory Tract InfectionActive, not recruiting

DysmenorrheaActive, not recruiting

Back PainActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

OsteoarthritisActive, not recruiting

Respiratory Tract InfectionPhase 3

Active, not recruiting

DysmenorrheaPhase 3

Active, not recruiting

Back PainPhase 3

Active, not recruiting

Rheumatoid ArthritisPhase 3

Active, not recruiting

OsteoarthritisApproved

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Pelubiprofen

Daewon Pharmaceutical Co., Ltd.

Approved

1 2

Rituxan

Roche

Preclinical

61 3

Orencia

Bristol-Myers Squibb

Preclinical

47 4

Simponi

Johnson & Johnson

Preclinical

19 5

Enbrel

IImmunex

Preclinical

64 6

Arcoxia

Novartis

Preclinical

4 7

Ilaris

Novartis

Preclinical

3 8

Celexa

AbbVie

Preclinical

1 9

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 10

Kineret

SSwedish Orphan Biovitrum

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Phase 12 trials

Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR and Pelubiprofen SR (as a Pelubiprofen 45 mg) Tablet in Healthy Subjects

Completed· Daewon Pharmaceutical Co., Ltd. logo

Daewon Pharmaceutical Co., Ltd.·Phase 1·NCT01870102

Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR TID and Pelubiprofen SR (as a Pelubiprofen 90 mg) Tablet QD in Healthy Subjects

Completed· Daewon Pharmaceutical Co., Ltd. logo

Daewon Pharmaceutical Co., Ltd.·Phase 1·NCT01776697

Back pain1 trial

Phase 3 Study of DW-330SR2 and Pelubiprofen in Chronic Back Pain Patients

Completed· Daewon Pharmaceutical Co., Ltd. logo

Daewon Pharmaceutical Co., Ltd.·Phase 3·NCT02375633·166 enrolled

Respiratory tract infection1 trial

Phase 3 Study of Pelubiprofen & Loxoprofen in Patients With Upper Respiratory Tract Infection

Completed· Daewon Pharmaceutical Co., Ltd. logo

Daewon Pharmaceutical Co., Ltd.·Phase 3·NCT01779271·183 enrolled

Injury1 trial

Clinical Trial to Evaluate the Efficacy and Safety of 'Pelubiprofen Controlled Released Tab.' in Acute Traumatic Injury

Unknown status· Daewon Pharmaceutical Co., Ltd. logo

Daewon Pharmaceutical Co., Ltd.·Phase 3·NCT03874247·94 enrolled

Rheumatoid Arthritis1 trial

Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients

Completed· Daewon Pharmaceutical Co., Ltd. logo

Daewon Pharmaceutical Co., Ltd.·Phase 3·NCT01781702·120 enrolled

2 more indications

Dysmenorrhea1 trial

Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients With Primary Dysmenorrhea

Unknown status· Daewon Pharmaceutical Co., Ltd. logo

Daewon Pharmaceutical Co., Ltd.·Phase 3·NCT04541134·120 enrolled

Osteoarthritis1 trial

Phase IV Clinical Trial to Evaluate the Efficacy and Safety of PlbCR and Aceclofenac in the Treatment of Patients With Osteoarthritis of the Knee

Completed· Daewon Pharmaceutical Co., Ltd. logo

Daewon Pharmaceutical Co., Ltd.·Phase 4·NCT02682524·191 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Pelubiprofen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pelubiprofen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pelubiprofen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daewon Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Daewon Pharmaceutical Co., Ltd.

Pelubiprofen

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Phase 12 trials

Back pain1 trial

Respiratory tract infection1 trial

Injury1 trial

Rheumatoid Arthritis1 trial

Dysmenorrhea1 trial

Osteoarthritis1 trial

References

Drug Info

Quick Facts

Related News